If the EU is unable to pass a hotly anticipated artificial intelligence/machine learning (AI/ML) law by year’s end, it may face an uphill battle due to conflicting political interests, Brandon O’Shea said at the AI Summit held by the AFDO/RAPS Healthcare Products Collaborative.
O’Shea, senior regulatory affairs manager at GE Healthcare, noted that a lot has happened in the past year regarding AI/ML regulation in the EU, US and China. “‘Noisy’ is the way I would describe it,” he said.
The confusion stems from the fact that a lot of different people, with a lot of different views, are working in each of those regulatory regimes to develop AI/ML regulations that don’t just represent the medtech industry but touch on other concerns such as labor, education, gaming, surveillance, and even how such technology will affect job security. This, in turn, he added, is drawing in many more policymaking stakeholders outside the medtech industry…
